BRAF and melanoma: These were selected from a cohort of 243 melanoma patients who received TT or CPI in a 1L setting (data on a subcohort of patients that only received CPI or BRAF/MEKi therapy without subsequent vice versa treatment are reported in Supplementary Table S7).